Who are Hyalex's investors?

Hyalex's investors include Canaan Partners, OUP (Osage University Partners), Treo Ventures, Llc, Johnson & Johnson Innovation – JJDC.

How much funding has Hyalex raised?

Hyalex has disclosed $45.5M raised across 2 of its 3 known rounds.

Where is Hyalex headquartered?

Hyalex is headquartered in Lexington, US.

Hyalex

Lexington, US · Founded 2016 · Delaware corporation · 24 employees on LinkedIn · 4 known investors

Find your way into Hyalex

Paths you didn't know you had: your email and LinkedIn already hold routes to the Hyalex team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

HYALEX Orthopaedics develops a synthetic cartilage platform for joint repair in orthopaedic surgery. The company aims to restore damaged joints for patients undergoing surgical intervention.

Healthtech Medical Devices

Founders & leadership

Carl Vause Chief Executive Officer, President, DirectorCarl Vause is a former CEO of Soft Robotics Inc. and has held senior roles at 3M, Nestlé, and Smith & Nephew. He holds a BSEE from Virginia Military Institute and an MBA from London Business School, and served as a Naval Flight Officer in the United States Navy.

Mira Sahney President, CEO and Board Member2017–2021Mira Sahney has held executive and CEO roles at life sciences companies spanning aerospace, automotive, and industrial equipment sectors, with P&L responsibility across startups and established organizations. Her background includes leadership positions at Medtronic and Smith + Nephew, where she drove business turnarounds and growth initiatives, along with earlier success scaling healthcare businesses.

David MyungNamed on SEC filing

Board

Michael HawkinsBoard director

Wende Hutton Board directorGeneral Partner at Canaan Partners

William Harrington Board directorManaging Partner at OUP (Osage University Partners)

Brad Vale Board directorFounding General Partner at Treo Ventures, Llc

V. Kadir KadhiresanBoard director

Adam Gridley Member Board of DirectorsExecutive Officer, Director at Allay Therapeutics

Investors · 4

Canaan Partnerslisted by Canaan PartnersStamford · $500K – $20Mvia Wende Hutton · board

How we know: Canaan Partners's portfolio page · a partner's Signal profile · board seat on SEC Form D · funding news · Not right? Tell us

OUP (Osage University Partners)listed by OUP (Osage University Partners)Bala Cynwyd · $1M – $20M

How we know: OUP (Osage University Partners)'s portfolio page · a partner's Signal profile · Not right? Tell us

Treo Ventures, Llclisted by Treo Ventures, LlcMinneapolisvia Brad H. Vale · board

How we know: Treo Ventures, Llc's portfolio page · board seat on SEC Form D · Not right? Tell us

Johnson & Johnson Innovation – JJDCreportedNew Brunswick

How we know: a partner's Signal profile · press coverage · Not right? Tell us

Funding

SEC filings, press & company announcements

$45.5M disclosed across 2 of 3 rounds · 2017–2024

Undisclosed amountSeries AMar 2019
Source ↗

▶$14.9MraisedOct 2024 · 7 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Michael HawkinsDirector
Adam GridleyDirector
Wende HuttonDirector
David MyungDirector
William HarringtonDirector
Brad ValeDirector
Carl VauseExecutive Officer, Director

Offering amount: $18.1M
Amount sold: $14.9M
First sale: Sep 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$30.6MraisedJul 2021 · 22 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

V. Kadir KadhiresanDirector
Mira SahneyExecutive Officer, Director
Brad ValeDirector
Michael HawkinsDirector
Wende HuttonDirector
David MyungDirector
William HarringtonDirector

Offering amount: $34.9M
Amount sold: $30.6M
First sale: May 2017
Incorporated: Corporation, Delaware, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

Orthofix (NASDAQ:OFIX)Orthofix develops medical devices and surgical solutions for orthopedic procedures, with a focus on spine surgery and limb reconstruction. The company serves physicians and patients globally and emphasizes product quality, safety, and environmental responsibility in its operations.

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

OrganogenesisOrganogenesis is a regenerative medicine company that develops and commercializes products for the advanced wound care and surgical biologics markets, supplying clinicians and their patients. Its product portfolio includes tissue-based therapies such as Apligraf for wound care.

Companies working in the same space as Hyalex.

In the news

Hyalex Adds New Funding; Expanding Series A Total to $33MM - Hyalex Orthopaedics, Inc.hyalex.com · Mar 2019

Frequently asked questions

What does Hyalex do?: HYALEX Orthopaedics develops a synthetic cartilage platform for joint repair in orthopaedic surgery. The company aims to restore damaged joints for patients undergoing surgical intervention.
Who are Hyalex's investors?: Hyalex's investors include Canaan Partners, OUP (Osage University Partners), Treo Ventures, Llc, Johnson & Johnson Innovation – JJDC.
How much funding has Hyalex raised?: Hyalex has disclosed $45.5M raised across 2 of its 3 known rounds.
Where is Hyalex headquartered?: Hyalex is headquartered in Lexington, US.